BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Sells $24,695.40 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) CFO Troy Wichterman sold 1,042 shares of BioLife Solutions stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $23.70, for a total transaction of $24,695.40. Following the sale, the chief financial officer now owns 186,685 shares in the company, valued at $4,424,434.50. This represents a 0.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Troy Wichterman also recently made the following trade(s):

• On Wednesday, May 28th, Troy Wichterman sold 583 shares of BioLife Solutions stock. The shares were sold at an average price of $22.46, for a total transaction of $13,094.18.
• On Wednesday, April 9th, Troy Wichterman sold 932 shares of BioLife Solutions stock. The shares were sold at an average price of $20.11, for a total transaction of $18,742.52.
• On Tuesday, April 1st, Troy Wichterman sold 25,687 shares of BioLife Solutions stock. The shares were sold at an average price of $22.66, for a total value of $582,067.42.

BioLife Solutions Stock Performance

BLFS traded down $1.48 on Friday, reaching $21.83. The company had a trading volume of 533,607 shares, compared to its average volume of 403,597. The stock has a market cap of $1.04 billion, a P/E ratio of -20.58 and a beta of 1.82. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. BioLife Solutions, Inc. has a fifty-two week low of $18.70 and a fifty-two week high of $29.55. The company's fifty day moving average is $22.69 and its 200 day moving average is $25.00.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last announced its earnings results on Thursday, May 8th. The medical equipment provider reported $0.04 earnings per share for the quarter, topping analysts' consensus estimates of ($0.03) by $0.07. The company had revenue of $23.94 million for the quarter, compared to analyst estimates of $22.22 million. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. As a group, analysts predict that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on BLFS. HC Wainwright reaffirmed a "buy" rating and set a $30.00 price objective on shares of BioLife Solutions in a research note on Tuesday, May 13th. Wall Street Zen cut BioLife Solutions from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to MarketBeat, BioLife Solutions has a consensus rating of "Moderate Buy" and a consensus target price of $31.17.

Institutional Trading of BioLife Solutions

A number of hedge funds and other institutional investors have recently modified their holdings of BLFS. Rhumbline Advisers grew its stake in shares of BioLife Solutions by 0.7% in the first quarter. Rhumbline Advisers now owns 83,227 shares of the medical equipment provider's stock worth $1,901,000 after purchasing an additional 566 shares during the last quarter. Strs Ohio bought a new position in BioLife Solutions during the first quarter worth $153,000. Jane Street Group LLC acquired a new position in BioLife Solutions in the first quarter valued at $1,091,000. Uniplan Investment Counsel Inc. grew its holdings in BioLife Solutions by 0.8% during the 1st quarter. Uniplan Investment Counsel Inc. now owns 247,378 shares of the medical equipment provider's stock worth $5,650,000 after acquiring an additional 1,861 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of BioLife Solutions by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,422 shares of the medical equipment provider's stock worth $489,000 after acquiring an additional 914 shares in the last quarter. Institutional investors own 93.24% of the company's stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.